{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T15:44:07Z","timestamp":1793375047686,"version":"4.5.0"},"reference-count":121,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CJASN"],"published-print":{"date-parts":[[2018,2]]},"abstract":"<jats:p>Thrombotic microangiopathy can manifest in a diverse range of diseases and is characterized by thrombocytopenia, microangiopathic hemolytic anemia, and organ injury, including AKI. It can be associated with significant morbidity and mortality, but a systematic approach to investigation and prompt initiation of supportive management and, in some cases, effective specific treatment can result in good outcomes. This review considers the classification, pathology, epidemiology, characteristics, and pathogenesis of the thrombotic microangiopathies, and outlines a pragmatic approach to diagnosis and management.<\/jats:p>","DOI":"10.2215\/cjn.00620117","type":"journal-article","created":{"date-parts":[[2017,10,17]],"date-time":"2017-10-17T20:25:32Z","timestamp":1508271932000},"page":"300-317","source":"Crossref","is-referenced-by-count":344,"title":["Thrombotic Microangiopathy and the Kidney"],"prefix":"10.2215","volume":"13","clinical-trial-number":[{"clinical-trial-number":"nct02336516","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02205541","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01029587","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02205541","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01029587","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Vicky","family":"Brocklebank","sequence":"first","affiliation":[{"name":"National Renal Complement Therapeutics Centre, Newcastle upon Tyne, Hospitals National Health Service Foundation Trust, Newcastle upon Tyne, UK;"},{"name":"Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrina M.","family":"Wood","sequence":"additional","affiliation":[{"name":"Department of Cellular Pathology, Newcastle upon Tyne Hospitals National Health Service Foundation Trust, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Kavanagh","sequence":"additional","affiliation":[{"name":"National Renal Complement Therapeutics Centre, Newcastle upon Tyne, Hospitals National Health Service Foundation Trust, Newcastle upon Tyne, UK;"},{"name":"Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2017,10,17]]},"reference":[{"key":"B1-20230813","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1056\/NEJMra020528","article-title":"Thrombotic microangiopathies","volume":"347","author":"Moake","year":"2002","journal-title":"N Engl J Med"},{"key":"B2-20230813","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1056\/NEJMra1312353","article-title":"Syndromes of thrombotic microangiopathy","volume":"371","author":"George","year":"2014","journal-title":"N Engl J Med"},{"key":"B3-20230813","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.imbio.2011.07.028","article-title":"Complement-mediated injury and protection of endothelium: Lessons from atypical haemolytic uraemic syndrome","volume":"217","author":"Kerr","year":"2012","journal-title":"Immunobiology"},{"key":"B4-20230813","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.molimm.2015.03.246","article-title":"Atypical aHUS: State of the art","volume":"67","author":"Nester","year":"2015","journal-title":"Mol Immunol"},{"key":"B6-20230813","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.kint.2016.10.005","article-title":"Atypical hemolytic uremic syndrome and C3 glomerulopathy: Conclusions from a \u201cKidney Disease: Improving Global Outcomes\u201d (KDIGO) controversies conference","volume":"91","author":"Goodship","year":"2017","journal-title":"Kidney Int"},{"key":"B7-20230813","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1093\/ndt\/gft220","article-title":"Atypical haemolytic uraemic syndrome with underlying glomerulopathies. A case series and a review of the literature","volume":"28","author":"Manenti","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"B8-20230813","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1681\/ASN.2010111130","article-title":"A clinicopathologic study of thrombotic microangiopathy in IgA nephropathy","volume":"23","author":"El Karoui","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"B9-20230813","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/RHU.0000000000000425","article-title":"Renal thrombotic microangiopathy in proliferative lupus nephritis: Risk factors and clinical outcomes: A Case-Control study","volume":"22","author":"Barrera-Vargas","year":"2016","journal-title":"J Clin Rheumatol"},{"key":"B10-20230813","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/jth.13189","article-title":"The role of ADAMTS-13 activity and complement mutational analysis in differentiating acute thrombotic microangiopathies","volume":"14","author":"Phillips","year":"2016","journal-title":"J Thromb Haemost"},{"key":"B12-20230813","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/ni.1923","article-title":"Complement: A key system for immune surveillance and homeostasis","volume":"11","author":"Ricklin","year":"2010","journal-title":"Nat Immunol"},{"key":"B13-20230813","doi-asserted-by":"crossref","DOI":"10.1093\/ckj\/sfx081","article-title":"Complement C5 inhibiting therapy for the thrombotic microangiopathies: Accumulating evidence, but not a panacea","author":"Brocklebank","year":"2017","journal-title":"Clin Kidney J"},{"key":"B14-20230813","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.semnephrol.2013.08.003","article-title":"Atypical hemolytic uremic syndrome","volume":"33","author":"Kavanagh","year":"2013","journal-title":"Semin Nephrol"},{"key":"B15-20230813","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1111\/j.1523-1755.1998.00824.x","article-title":"Genetic studies into inherited and sporadic hemolytic uremic syndrome","volume":"53","author":"Warwicker","year":"1998","journal-title":"Kidney Int"},{"key":"B16-20230813","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/ajt.12077","article-title":"Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome","volume":"13","author":"Le Quintrec","year":"2013","journal-title":"Am J Transplant"},{"key":"B17-20230813","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1055\/s-0030-1262887","article-title":"Transplantation in atypical hemolytic uremic syndrome","volume":"36","author":"Kavanagh","year":"2010","journal-title":"Semin Thromb Hemost"},{"key":"B18-20230813","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s00467-013-2722-2","article-title":"Liver-kidney transplantation to cure atypical HUS: Still an option post-eculizumab?","volume":"29","author":"Saland","year":"2014","journal-title":"Pediatr Nephrol"},{"key":"B19-20230813","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1681\/ASN.2004050380","article-title":"Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome","volume":"16","author":"Dragon-Durey","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"B20-20230813","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.4049\/jimmunol.1200679","article-title":"Overall neutralization of complement factor H by autoantibodies in the acute phase of the autoimmune form of atypical hemolytic uremic syndrome","volume":"189","author":"Blanc","year":"2012","journal-title":"J Immunol"},{"key":"B21-20230813","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1182\/blood-2009-05-221549","article-title":"Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome","volume":"115","author":"Moore","year":"2010","journal-title":"Blood"},{"key":"B22-20230813","article-title":"Factor H: Autoantibody associated atypical haemolytic uraemic syndrome in children in the United Kingdom and Ireland [published online ahead of print July 24, 2017]","author":"Brocklebank","journal-title":"Kidney Int"},{"key":"B23-20230813","doi-asserted-by":"crossref","first-page":"417","DOI":"10.2215\/CJN.05750611","article-title":"Factor I autoantibodies in patients with atypical hemolytic uremic syndrome: Disease-associated or an epiphenomenon?","volume":"7","author":"Kavanagh","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"B24-20230813","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00467-015-3076-8","article-title":"An international consensus approach to the management of atypical hemolytic uremic syndrome in children","volume":"31","author":"Loirat","year":"2016","journal-title":"Pediatr Nephrol"},{"key":"B25-20230813","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1055\/s-0034-1376154","article-title":"Diagnosis and treatment of the hemolytic uremic syndrome disease spectrum in developing regions","volume":"40","author":"Hofer","year":"2014","journal-title":"Semin Thromb Hemost"},{"key":"B26-20230813","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N Engl J Med"},{"key":"B27-20230813","doi-asserted-by":"crossref","first-page":"554","DOI":"10.2215\/CJN.04760512","article-title":"Genetics and outcome of atypical hemolytic uremic syndrome: A nationwide French series comparing children and adults","volume":"8","author":"Fremeaux-Bacchi","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"B28-20230813","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.2215\/CJN.02210310","article-title":"Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype","volume":"5","author":"Noris","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"B29-20230813","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/ki.2014.423","article-title":"Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies","volume":"87","author":"Licht","year":"2015","journal-title":"Kidney Int"},{"key":"B30-20230813","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1053\/j.ajkd.2015.12.034","article-title":"Terminal complement inhibitor eculizumab in adult patients with atypical hemolytic uremic syndrome: A single-arm, open-label trial","volume":"68","author":"Fakhouri","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"B31-20230813","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.kint.2015.11.026","article-title":"Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome","volume":"89","author":"Greenbaum","year":"2016","journal-title":"Kidney Int"},{"key":"B33-20230813","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.trsl.2014.10.010","article-title":"Anticomplement C5 therapy with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome","volume":"165","author":"Wong","year":"2015","journal-title":"Transl Res"},{"key":"B34-20230813","doi-asserted-by":"crossref","first-page":"50","DOI":"10.2215\/CJN.06440616","article-title":"Pathogenic variants in complement genes and risk of atypical hemolytic uremic syndrome relapse after eculizumab discontinuation","volume":"12","author":"Fakhouri","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"B35-20230813","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.2169\/internalmedicine.52.9180","article-title":"Drug-induced thrombotic thrombocytopenic purpura successfully treated with recombinant human soluble thrombomodulin","volume":"52","author":"Nishijima","year":"2013","journal-title":"Intern Med"},{"key":"B36-20230813","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/ng.2590","article-title":"Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome","volume":"45","author":"Lemaire","year":"2013","journal-title":"Nat Genet"},{"key":"B37-20230813","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1681\/ASN.2015101189","article-title":"Thrombotic microangiopathy in inverted formin 2-mediated renal disease","volume":"28","author":"Challis","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"B38-20230813","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/QCO.0000000000000279","article-title":"Infections associated with the use of eculizumab: Recommendations for prevention and prophylaxis","volume":"29","author":"Benamu","year":"2016","journal-title":"Curr Opin Infect Dis"},{"key":"B39-20230813","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00277-017-2924-y","article-title":"Serologic response to meningococcal vaccination in patients with paroxysmal nocturnal hemoglobinuria (PNH) chronically treated with the terminal complement inhibitor eculizumab","volume":"96","author":"Alashkar","year":"2017","journal-title":"Ann Hematol"},{"key":"B40-20230813","doi-asserted-by":"crossref","first-page":"e1506","DOI":"10.1542\/peds.2014-3503","article-title":"Case report: Benefits and challenges of long-term eculizumab in atypical hemolytic uremic syndrome","volume":"135","author":"Cullinan","year":"2015","journal-title":"Pediatrics"},{"key":"B41-20230813","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1111\/ajt.12032","article-title":"Meningococcal sepsis complicating eculizumab treatment despite prior vaccination","volume":"13","author":"Struijk","year":"2013","journal-title":"Am J Transplant"},{"key":"B42-20230813","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s00467-014-2990-5","article-title":"Eculizumab hepatotoxicity in pediatric aHUS","volume":"30","author":"Hayes","year":"2015","journal-title":"Pediatr Nephrol"},{"key":"B43-20230813","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1681\/ASN.2011121186","article-title":"Pathology after eculizumab in dense deposit disease and C3 GN","volume":"23","author":"Herlitz","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"B44-20230813","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/00062752-200309000-00003","article-title":"The association of pregnancy with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome","volume":"10","author":"George","year":"2003","journal-title":"Curr Opin Hematol"},{"key":"B45-20230813","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/nrneph.2012.214","article-title":"Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies","volume":"8","author":"Zuber","year":"2012","journal-title":"Nat Rev Nephrol"},{"key":"B46-20230813","first-page":"149","article-title":"Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the writing committee of the american society for apheresis: The seventh special issue","volume":"31","author":"Schwartz","year":"2016","journal-title":"J Clin Apher"},{"key":"B47-20230813","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1182\/blood-2011-03-341131","article-title":"A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura","volume":"118","author":"Scully","year":"2011","journal-title":"Blood"},{"key":"B48-20230813","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/bjh.13408","article-title":"A phase-II sequential case-series study of all patients presenting to four plasma exchange centres with presumed relapsed\/refractory thrombotic thrombocytopenic purpura treated with rituximab","volume":"170","author":"Clark","year":"2015","journal-title":"Br J Haematol"},{"key":"B49-20230813","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1002\/ajh.24559","article-title":"Efficacy of a rituximab regimen based on B cell depletion in thrombotic thrombocytopenic purpura with suboptimal response to standard treatment: Results of a phase II, multicenter non-comparative study","volume":"91","author":"Benhamou","year":"2016","journal-title":"Am J Hematol"},{"key":"B50-20230813","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00467-016-3399-0","article-title":"Renal thrombotic microangiopathy in patients with cblC defect: Review of an under-recognized entity","volume":"32","author":"Beck","year":"2017","journal-title":"Pediatr Nephrol"},{"key":"B51-20230813","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1182\/blood-2014-06-579953","article-title":"Loss of DGK\u03b5 induces endothelial cell activation and death independently of complement activation","volume":"125","author":"Bruneau","year":"2015","journal-title":"Blood"},{"key":"B52-20230813","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.2215\/CJN.08520814","article-title":"Characterization of a new DGKE intronic mutation in genetically unsolved cases of familial atypical hemolytic uremic syndrome","volume":"10","author":"Mele","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"B53-20230813","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1681\/ASN.2013080886","article-title":"Phenotypic expansion of DGKE-associated diseases","volume":"25","author":"Westland","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"B54-20230813","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.2215\/CJN.01640214","article-title":"Complement mutations in diacylglycerol kinase-\u03b5-associated atypical hemolytic uremic syndrome","volume":"9","author":"S\u00e1nchez Chinchilla","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"B55-20230813","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1681\/ASN.2012090903","article-title":"DGKE variants cause a glomerular microangiopathy that mimics membranoproliferative GN","volume":"24","author":"Ozaltin","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"B56-20230813","doi-asserted-by":"crossref","first-page":"E1445","DOI":"10.1002\/humu.21256","article-title":"Mutations in alternative pathway complement proteins in American patients with atypical hemolytic uremic syndrome","volume":"31","author":"Maga","year":"2010","journal-title":"Hum Mutat"},{"key":"B57-20230813","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1056\/NEJMoa0810739","article-title":"Thrombomodulin mutations in atypical hemolytic-uremic syndrome","volume":"361","author":"Delvaeye","year":"2009","journal-title":"N Engl J Med"},{"key":"B58-20230813","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1681\/ASN.2013050453","article-title":"Comprehensive genetic analysis of complement and coagulation genes in atypical hemolytic uremic syndrome","volume":"25","author":"Bu","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"B59-20230813","first-page":"1073","article-title":"Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome","volume":"365","author":"Tarr","year":"2005","journal-title":"Lancet"},{"key":"B60-20230813","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1093\/ndt\/gfs394","article-title":"Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-toxin-producing E. coli O104:H4 induced haemolytic-uraemic syndrome: An analysis of the German STEC-HUS registry","volume":"27","author":"Kielstein","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"B61-20230813","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1128\/JCM.44.2.313-317.2006","article-title":"Shiga toxins present in the gut and in the polymorphonuclear leukocytes circulating in the blood of children with hemolytic-uremic syndrome","volume":"44","author":"Brigotti","year":"2006","journal-title":"J Clin Microbiol"},{"key":"B62-20230813","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.3390\/toxins2122769","article-title":"Escherichia coli Shiga toxin mechanisms of action in renal disease","volume":"2","author":"Obrig","year":"2010","journal-title":"Toxins (Basel)"},{"key":"B63-20230813","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1097\/01.ASN.0000027873.85792.52","article-title":"Molecular basis for high renal cell sensitivity to the cytotoxic effects of shigatoxin-1: Upregulation of globotriaosylceramide expression","volume":"13","author":"Hughes","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"B64-20230813","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0022-3476(94)70002-8","article-title":"Escherichia coli O 157:H7-associated hemolytic-uremic syndrome after ingestion of contaminated hamburgers","volume":"125","author":"Brandt","year":"1994","journal-title":"J Pediatr"},{"key":"B65-20230813","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1093\/ckj\/sfx030","article-title":"Rare genetic variants in Shiga toxin\u2013associated haemolytic uraemic syndrome: Genetic analysis prior to transplantation is essential","volume":"10","author":"Dowen","year":"2017","journal-title":"Clin Kidney J"},{"key":"B66-20230813","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1007\/s00467-012-2383-6","article-title":"Long-term outcomes of Shiga toxin hemolytic uremic syndrome","volume":"28","author":"Spinale","year":"2013","journal-title":"Pediatr Nephrol"},{"key":"B67-20230813","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1056\/NEJMc1100859","article-title":"Eculizumab in severe Shiga-toxin-associated HUS","volume":"364","author":"Lapeyraque","year":"2011","journal-title":"N Engl J Med"},{"key":"B68-20230813","doi-asserted-by":"crossref","first-page":"e4565","DOI":"10.1136\/bmj.e4565","article-title":"Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: Case-control study","volume":"345","author":"Menne","year":"2012","journal-title":"BMJ"},{"key":"B69-20230813","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1093\/cid\/cis531","article-title":"An outbreak of Shiga toxin-producing Escherichia coli O104:H4 hemolytic uremic syndrome in Germany: Presentation and short-term outcome in children","volume":"55","author":"Loos","year":"2012","journal-title":"Clin Infect Dis"},{"key":"B70-20230813","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.imbio.2011.07.022","article-title":"Is complement a culprit in infection-induced forms of haemolytic uraemic syndrome?","volume":"217","author":"Johnson","year":"2012","journal-title":"Immunobiology"},{"key":"B71-20230813","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/MOP.0b013e32835d7f2c","article-title":"Update on Streptococcus pneumoniae associated hemolytic uremic syndrome","volume":"25","author":"Spinale","year":"2013","journal-title":"Curr Opin Pediatr"},{"key":"B72-20230813","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1097\/INF.0b013e3182191c58","article-title":"Streptococcus pneumoniae-associated hemolytic uremic syndrome among children in North America","volume":"30","author":"Banerjee","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"B73-20230813","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/bmb\/ldl004","article-title":"Atypical haemolytic uraemic syndrome","volume":"77-78","author":"Kavanagh","year":"2006","journal-title":"Br Med Bull"},{"key":"B74-20230813","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/nchembio.1696","article-title":"Structural basis for sialic acid-mediated self-recognition by complement factor H","volume":"11","author":"Blaum","year":"2015","journal-title":"Nat Chem Biol"},{"key":"B75-20230813","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1046\/j.1523-1755.2003.00743.x","article-title":"Light at the end of the TUNEL: HIV-associated thrombotic microangiopathy","volume":"63","author":"Alpers","year":"2003","journal-title":"Kidney Int"},{"key":"B76-20230813","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1093\/ndt\/14.6.1578","article-title":"Acute renal failure in the course of HIV infection: A single-institution retrospective study of ninety-two patients and sixty renal biopsies","volume":"14","author":"Peraldi","year":"1999","journal-title":"Nephrol Dial Transplant"},{"issue":"Suppl 5","key":"B77-20230813","doi-asserted-by":"crossref","first-page":"S267","DOI":"10.1086\/422363","article-title":"HIV-associated thrombotic microangiopathy in the era of highly active antiretroviral therapy: An observational study","volume":"39","author":"Becker","year":"2004","journal-title":"Clin Infect Dis"},{"key":"B78-20230813","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1182\/blood-2005-10-007252","article-title":"Genetics of HUS: The impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome","volume":"108","author":"Caprioli","year":"2006","journal-title":"Blood"},{"key":"B79-20230813","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.2215\/CJN.13121211","article-title":"Obstetric nephrology: AKI and thrombotic microangiopathies in pregnancy","volume":"7","author":"Fakhouri","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"B80-20230813","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1182\/asheducation-2015.1.644","article-title":"Syndromes of thrombotic microangiopathy associated with pregnancy","volume":"2015","author":"George","year":"2015","journal-title":"Hematology (Am Soc Hematol Educ Program)"},{"key":"B82-20230813","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.2215\/CJN.00280117","article-title":"Hemolytic uremic syndrome in pregnancy and postpartum","volume":"12","author":"Bruel","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"B83-20230813","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1056\/NEJMoa1502950","article-title":"Eculizumab in pregnant patients with paroxysmal nocturnal hemoglobinuria","volume":"373","author":"Kelly","year":"2015","journal-title":"N Engl J Med"},{"key":"B85-20230813","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1182\/blood-2014-02-553131","article-title":"Thrombotic thrombocytopenic purpura and pregnancy: Presentation, management, and subsequent pregnancy outcomes","volume":"124","author":"Scully","year":"2014","journal-title":"Blood"},{"key":"B86-20230813","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S0140-6736(10)60279-6","article-title":"Pre-eclampsia","volume":"376","author":"Steegers","year":"2010","journal-title":"Lancet"},{"key":"B87-20230813","doi-asserted-by":"crossref","first-page":"e1001013","DOI":"10.1371\/journal.pmed.1001013","article-title":"Mutations in complement regulatory proteins predispose to preeclampsia: A genetic analysis of the PROMISSE cohort","volume":"8","author":"Salmon","year":"2011","journal-title":"PLoS Med"},{"key":"B88-20230813","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1182\/blood-2014-11-611335","article-title":"Drug-induced thrombotic microangiopathy: A systematic review of published reports","volume":"125","author":"Al-Nouri","year":"2015","journal-title":"Blood"},{"key":"B89-20230813","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1182\/blood.V77.2.306.306","article-title":"Quinine-induced immune thrombocytopenia associated with hemolytic uremic syndrome: A new clinical entity","volume":"77","author":"Gottschall","year":"1991","journal-title":"Blood"},{"key":"B90-20230813","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1182\/blood-2016-05-715987","article-title":"Type I interferon causes thrombotic microangiopathy by a dose-dependent toxic effect on the microvasculature","volume":"128","author":"Kavanagh","year":"2016","journal-title":"Blood"},{"key":"B91-20230813","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1056\/NEJMoa0707330","article-title":"VEGF inhibition and renal thrombotic microangiopathy","volume":"358","author":"Eremina","year":"2008","journal-title":"N Engl J Med"},{"key":"B92-20230813","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1111\/bjh.12303","article-title":"Ticlopidine-associated ADAMTS13 activity deficient thrombotic thrombocytopenic purpura in 22 persons in Japan: A report from the Southern Network on Adverse Reactions (SONAR)","volume":"161","author":"Bennett","year":"2013","journal-title":"Br J Haematol"},{"key":"B93-20230813","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.blre.2014.09.001","article-title":"De novo thrombotic microangiopathy after non-renal solid organ transplantation","volume":"28","author":"Verbiest","year":"2014","journal-title":"Blood Rev"},{"key":"B94-20230813","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1111\/j.1432-2277.2006.00354.x","article-title":"Thrombotic microangiopathy after kidney transplantation","volume":"19","author":"Ponticelli","year":"2006","journal-title":"Transpl Int"},{"key":"B95-20230813","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.trre.2013.07.003","article-title":"Targeted strategies in the prevention and management of atypical HUS recurrence after kidney transplantation","volume":"27","author":"Zuber","year":"2013","journal-title":"Transplant Rev (Orlando)"},{"key":"B96-20230813","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1111\/j.1600-6143.2008.02297.x","article-title":"Complement mutation-associated de novo thrombotic microangiopathy following kidney transplantation","volume":"8","author":"Le Quintrec","year":"2008","journal-title":"Am J Transplant"},{"key":"B98-20230813","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1182\/blood-2015-08-663435","article-title":"The genetic fingerprint of susceptibility for transplant-associated thrombotic microangiopathy","volume":"127","author":"Jodele","year":"2016","journal-title":"Blood"},{"key":"B99-20230813","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/bmt.2016.253","article-title":"Is complement blockade an acceptable therapeutic strategy for hematopoietic cell transplant-associated thrombotic microangiopathy?","volume":"52","author":"Dhakal","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"B100-20230813","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1182\/blood-2013-05-501445","article-title":"Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy","volume":"122","author":"Jodele","year":"2013","journal-title":"Blood"},{"key":"B102-20230813","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.kint.2017.02.025","article-title":"Severe hypertension with renal thrombotic microangiopathy: What happened to the usual suspect?","volume":"91","author":"Van Laecke","year":"2017","journal-title":"Kidney Int"},{"key":"B103-20230813","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/j.kint.2016.12.009","article-title":"Patients with hypertension-associated thrombotic microangiopathy may present with complement abnormalities","volume":"91","author":"Timmermans","year":"2017","journal-title":"Kidney Int"},{"key":"B104-20230813","doi-asserted-by":"crossref","first-page":"147","DOI":"10.5414\/CNP73147","article-title":"Severe renal failure and microangiopathic hemolysis induced by malignant hypertension--case series and review of literature","volume":"73","author":"Shavit","year":"2010","journal-title":"Clin Nephrol"},{"key":"B105-20230813","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1053\/j.ajkd.2015.02.340","article-title":"Thrombotic microangiopathy, cancer, and cancer drugs","volume":"66","author":"Izzedine","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"B106-20230813","first-page":"908","article-title":"Systemic malignancies as a cause of unexpected microangiopathic hemolytic anemia and thrombocytopenia","volume":"25","author":"George","year":"2011","journal-title":"Oncology (Williston Park)"},{"key":"B107-20230813","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1200\/JCO.1989.7.6.781","article-title":"Cancer-associated hemolytic-uremic syndrome: Analysis of 85 cases from a national registry","volume":"7","author":"Lesesne","year":"1989","journal-title":"J Clin Oncol"},{"key":"B108-20230813","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1634\/theoncologist.2009-0067","article-title":"Cancer awareness in atypical thrombotic microangiopathies","volume":"14","author":"Oberic","year":"2009","journal-title":"Oncologist"},{"key":"B109-20230813","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1093\/ndt\/gfg470","article-title":"Familial mesangio-capillary glomerulonephritis with initial presentation as haemolytic uraemic syndrome","volume":"19","author":"Cooper","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"B110-20230813","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.molimm.2015.03.012","article-title":"The role of complement in C3 glomerulopathy","volume":"67","author":"Zipfel","year":"2015","journal-title":"Mol Immunol"},{"key":"B111-20230813","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/nrneph.2016.124","article-title":"Scleroderma renal crisis and renal involvement in systemic sclerosis","volume":"12","author":"Woodworth","year":"2016","journal-title":"Nat Rev Nephrol"},{"key":"B112-20230813","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.autrev.2016.09.010","article-title":"Catastrophic antiphospholipid syndrome (CAPS): Descriptive analysis of 500 patients from the international CAPS registry","volume":"15","author":"Rodr\u00edguez-Pint\u00f3","year":"2016","journal-title":"Autoimmun Rev"},{"key":"B113-20230813","article-title":"Haemolytic uraemic syndrome [published online ahead of print February 25, 2017]","author":"Fakhouri","journal-title":"Lancet"},{"key":"B114-20230813","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1053\/j.ajkd.2008.07.038","article-title":"Interventions for hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: A systematic review of randomized controlled trials","volume":"53","author":"Michael","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"B115-20230813","doi-asserted-by":"crossref","first-page":"590","DOI":"10.3201\/eid1104.040833","article-title":"Childhood hemolytic uremic syndrome, United Kingdom and Ireland","volume":"11","author":"Lynn","year":"2005","journal-title":"Emerg Infect Dis"},{"key":"B116-20230813","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/nrneph.2012.195","article-title":"STEC-HUS, atypical HUS and TTP are all diseases of complement activation","volume":"8","author":"Noris","year":"2012","journal-title":"Nat Rev Nephrol"},{"key":"B117-20230813","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jpeds.2007.03.055","article-title":"Hemolytic uremic syndrome associated with invasive pneumococcal disease: The United kingdom experience","volume":"151","author":"Waters","year":"2007","journal-title":"J Pediatr"},{"key":"B118-20230813","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s00467-003-1382-z","article-title":"Pneumococcus-induced T-antigen activation in hemolytic uremic syndrome and anemia","volume":"19","author":"Cochran","year":"2004","journal-title":"Pediatr Nephrol"},{"key":"B119-20230813","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1111\/j.1440-1754.2009.01603.x","article-title":"Ten years of pneumococcal-associated haemolytic uraemic syndrome in New Zealand children","volume":"45","author":"Prestidge","year":"2009","journal-title":"J Paediatr Child Health"},{"key":"B120-20230813","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1086\/513804","article-title":"A randomized, double-blind trial of valaciclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection. AIDS Clinical Trials Group Protocol 204\/Glaxo Wellcome 123-014 International CMV Prophylaxis study group","volume":"177","author":"Feinberg","year":"1998","journal-title":"J Infect Dis"},{"key":"B122-20230813","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2165\/00002018-200124070-00002","article-title":"Drug-induced thrombotic microangiopathy: Incidence, prevention and management","volume":"24","author":"Pisoni","year":"2001","journal-title":"Drug Saf"},{"key":"B123-20230813","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.ajkd.2003.07.008","article-title":"Thrombotic microangiopathy after renal transplantation in the United States","volume":"42","author":"Reynolds","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"B124-20230813","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1161\/01.HYP.0000151620.17905.ee","article-title":"Microangiopathic hemolysis and renal failure in malignant hypertension","volume":"45","author":"van den Born","year":"2005","journal-title":"Hypertension"},{"key":"B125-20230813","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.amjhyper.2007.02.018","article-title":"The renin-angiotensin system in malignant hypertension revisited: plasma renin activity, microangiopathic hemolysis, and renal failure in malignant hypertension","volume":"20","author":"van den Born","year":"2007","journal-title":"Am J Hypertens"},{"key":"B126-20230813","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3109\/10641963.2010.503303","article-title":"Clinical features of malignant hypertension with thrombotic microangiopathy","volume":"33","author":"Akimoto","year":"2011","journal-title":"Clin Exp Hypertens"},{"key":"B127-20230813","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/1471-2369-13-71","article-title":"Long-term renal outcome in patients with malignant hypertension: A retrospective cohort study","volume":"13","author":"Amraoui","year":"2012","journal-title":"BMC Nephrol"},{"key":"B128-20230813","doi-asserted-by":"crossref","first-page":"757","DOI":"10.2215\/CJN.02870311","article-title":"Evaluation of clinical outcomes and renal vascular pathology among patients with lupus","volume":"7","author":"Barber","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"B129-20230813","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s11926-015-0551-y","article-title":"Recent developments in the classification, evaluation, pathophysiology, and management of scleroderma renal crisis","volume":"18","author":"Ghossein","year":"2016","journal-title":"Curr Rheumatol Rep"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01277230-201802000-00018","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:37:22Z","timestamp":1786369042000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01277230-201802000-00018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,17]]},"references-count":121,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.00620117","relation":{},"ISSN":["1555-9041","1555-905X"],"issn-type":[{"value":"1555-9041","type":"print"},{"value":"1555-905X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,17]]}}}